98%
921
2 minutes
20
Importance: Chronic total occlusion percutaneous coronary intervention (CTO-PCI) is not usually offered because of skepticism about long-term clinical benefits.
Objective: To assess the association of successful CTO-PCI with quality of life by analyzing the relevant domains of the Seattle Angina Questionnaire (SAQ).
Data Sources: PubMed, EMBASE, Web of Science, Google Scholar, and Cochrane databases were searched to identify randomized trials and observational studies specifically addressing quality of life domains of SAQ from January 2010 to June 2022.
Study Selection: Studies included reporting SAQ metrics such as angina frequency, physical limitation, and quality of life, before and after CTO-PCI.
Data Extraction And Synthesis: The present study was performed according to the Cochrane Collaboration and Preferred Reporting Items for Systematic Reviews and Meta-Analyses statements, in which fixed-effect or random-effect models with generic inverse-variance weighting depending on statistical homogeneity were applied. Data were extracted by 3 independent reviewers.
Outcomes And Measures: The primary outcome was angina frequency; physical limitation and quality of life were assessed as secondary outcomes.
Results: Seven prospective randomized or observational studies (2500 patients) were included, with a mean (SD) participant age of 61.2 (2.1) years. CTO-PCI was associated with significantly improved quality-of-life metrics during a mean (SD) follow-up of 14.8 (16.3) months. In patients with successful procedures, angina episodes became less frequent (mean [SD] difference for SAQ angina frequency of 12.9 [3.1] survey points [95% CI, 7.1-19.8 survey points]; standardized mean difference was 0.54 [95% CI, 0.21-0.92]; P = .002; I2 = 86.4%) and they experienced less physical activity limitation (mean [SD] difference for SAQ physical limitation of 9.7 [6.2] survey points [95% CI, 3.5-16.2 survey points]; standardized mean difference was 0.42 [95% CI, 0.24-0.55]; P < .001; I2 = 20.9%), and greater quality-of-life domain (mean [SD] difference for SAQ quality of life of 14.9 [3.5] survey points [95% CI, 7.7-22.5 survey points]; standardized mean difference was 0.41 [95% CI, 0.25-0.61]; P < .001; I2 = 58.8%) compared with patients with optimal medical therapy or failed procedure. Furthermore, follow-up duration (point estimate, 0.03; 95% CI, 0.01-0.04; P = .01) was associated with a significant decrease in angina frequency in meta-regression analysis.
Conclusions And Relevance: In this systematic review and meta-analysis examining quality of life following CTO-PCI, successful procedures were associated with improved quality-of-life parameters compared with patients on optimal medical therapy or after failed CTO-PCI. These findings suggest support for using PCI to treat CTOs in symptomatic patients unresponsive to medical treatment.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359963 | PMC |
http://dx.doi.org/10.1001/jamanetworkopen.2023.24522 | DOI Listing |
Scand J Med Sci Sports
September 2025
Department of Dermatology and Allergy Biederstein, School of Medicine and Health, TUM University Hospital Rechts der Isar, Munich, Germany.
In wheat allergy dependent on augmentation factors (WALDA), allergic reactions occur when wheat ingestion is combined with exercise or rarely other augmentation factors. We analyzed clinical characteristics and disease burden in recreationally active and trained individuals with WALDA diagnosed by oral challenge test. Clinical characteristics, serological data, and quality of life (QOL) questionnaires were analyzed and completed with follow-up interviews.
View Article and Find Full Text PDFInt J Gynaecol Obstet
September 2025
Department of Gynecology and Obstetrics, Justus Liebig University Giessen, Giessen, Germany.
Even though uterine fibroids are a widespread condition, the range of approved medical treatment options remains limited. In fact, only a few drugs are officially approved for the therapy of fibroids. In both the USA and the European Medicines Agency region, selected gonadotropin-releasing hormone (GnRH) antagonists have been approved for this indication.
View Article and Find Full Text PDFJ Investig Allergol Clin Immunol
September 2025
Department of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Background And Objectives: Pollen-food allergy syndrome (PFAS) is a frequent comorbidity in individuals with hay fever. Identifying risk factors and allergen clusters can aid targeted interventions and management strategies. Objective: This study characterizes PFAS in patients with hay fever and identifies associated risk factors using the mobile health platform, AllerSearch.
View Article and Find Full Text PDFJ Sci Food Agric
September 2025
Microbial Biotechnology Research Group, School of Life Sciences and Technology, Institut Teknologi Bandung, Bandung, Indonesia.
Background: Secondary fermentation can reduce variability in cocoa bean quality caused by the spontaneous, uncontrolled nature of primary fermentation. However, its optimization remains unexplored. This study evaluated the improvement of secondary fermentation through the combined use of Citrus limon peel and inoculation with Candida tropicalis H1Y4-1 as a starter.
View Article and Find Full Text PDFStroke
September 2025
Department of Rehabilitation Medicine, West China Hospital, Sichuan University, Chengdu, China (H.Z., K.H., Q.G.).
Background: Poststroke cognitive impairment (PSCI) affects 30% to 50% of stroke survivors, severely impacting functional outcomes and quality of life. This study uses functional near-infrared spectroscopy (fNIRS) to assess task-evoked brain activation and its potential for stratifying the severity in patients with PSCI.
Method: A cross-sectional study was conducted at Nanchong Central Hospital between June 2023 and April 2024.